Space
PrivateA genuine technical first (the only firm to fly-around non-cooperative debris) wrapped in a pre-revenue cash-burning balance sheet trading at ~31x sales — the science works, the commercial P&L is a 2028+ promise, and the stock just halved because the promise slipped a year.
Research
The verdict
A genuine technical first (the only firm to fly-around non-cooperative debris) wrapped in a pre-revenue cash-burning balance sheet trading at ~31x sales — the science works, the commercial P&L is a 2028+ promise, and the stock just halved because the promise slipped a year.
Astroscale sells on-orbit servicing (OOS) — sending robotic spacecraft to rendezvous with, inspect, refuel, relocate, life-extend, or de-orbit other objects already in space. Four product lines ``:
The business is structured as a Tokyo holding company over four operating subsidiaries — Astroscale Japan, Astroscale U.S. (Denver), Astroscale Ltd (UK, Harwell), and Astroscale Israel. This geographic spread is deliberate: it lets the group win national-security and civil-space contracts in three blocs (JAXA/Japan MoD, US Space Force/Space Systems Command, UK Space Agency/ESA) that would never go to a single-jurisdiction vendor.
Revenue model — and the key nuance: the company reports "Project Income" = booked revenue + government grants/subsidies tied to specific missions . The gap between the two is large and telling: FY2026 Project Income was ¥11.5B but GAAP **revenue was only ¥5.94B** — i.e. roughly half of "income" is government grant money, not customer revenue. This is a development-stage contractor whose cash flows are dominated by milestone-funded government demonstration programs (ADRAS-J/J2, ELSA-M, COSMIC, US Refueler), not a recurring commercial service business — yet.
Main customers are governments and space agencies: JAXA, the UK Space Agency / ESA, the US Space Force / Space Systems Command, the Japanese Ministry of Defense, plus commercial anchors Eutelsat OneWeb (the ELSA-M target satellite) and a still-unnamed GEO operator ("Customer B") for the delayed LEXI-P life-extension contract ``.
Upstream inputs → Astroscale → end customer, named where sourceable ``:
n/a.Single-source / chokepoint dependencies: (1) launch cadence — every mission date is hostage to a launch provider, and two flagships ride first-generation small launchers; (2) government program continuity — JAXA's CRD2 phases, the UK COSMIC program, and US Space Force budgets are the de facto "suppliers" of demand, each subject to political/appropriations risk; (3) the target object itself — ELSA-M depends on a specific OneWeb satellite, ADRAS-J2 on a specific 2009 H-IIA upper stage ``. Names present → lens satisfied.
The one durable moat is demonstrated, non-cooperative RPO heritage. Astroscale is, on the public record, the only commercial company to have flown around and closely inspected a piece of non-cooperative large debris — a tumbling object with no docking aids, no GPS beacon, no cooperative attitude. ADRAS-J approached a ~3-tonne, 11 m H-IIA upper stage to 15 metres, performed controlled fly-around imaging at ~50 m, and validated autonomous collision-avoidance over a 293-day mission before de-orbiting ``. That is genuinely hard and genuinely first.
Moat assessment, ranked by durability:
Verdict on the moat: a real technical first protecting a market that doesn't commercially exist yet. The science is ahead; the economics are not moated.
The company does not publish a clean product-line revenue/EBIT split in the English sources available; what is sourceable is the government-vs-commercial composition and the backlog by program.
⇒ **~¥5.6B (~48%) is government grants/subsidies, ~¥5.9B is booked customer revenue**. The business is roughly half grant-funded., **down 14.6% from ¥44.4B at FY2025 year-end** . Major program lines: ADRAS-J2 ≈ ¥12B / $82M (JAXA CRD2 Phase II) ; UK **COSMIC** Phase 3 ≈ **¥12B** (now slipped a year) ; US Space Force Refueler ≈ $25.5M co-investment ; Japan MoD universal-terminal mechanism ≈ **¥1B** (Dec 2025–Mar 2028) .n/a.; +30.5% the prior framing) off a tiny base — but the **backlog is decelerating/peaking** (−14.6%), which the market read as a "peak-out" signal . Acceleration in the income statement, deceleration in the order book: the two diverge, and the order book is the leading indicator.The most recent print (results released 2026-06-12) ``:
| Metric | FY2026 (FYE Apr-26) | Prior | Source |
|---|---|---|---|
| Project Income | ¥11.5B (+89% YoY) | ¥6.1B FY25 | `` |
| GAAP revenue | ¥5.94B | ~¥6.9B FY25 (rev −13.9%) | `` |
| Operating loss | −¥9.98B | −¥9.97B FY25 | `` |
| Net loss | −¥6.70B (FX-aided) | n/a | `` |
| Cash & equivalents | ¥10.0B | n/a | `` |
| Backlog | ¥37.9B (−14.6% YoY) | ¥44.4B | `` |
| Equity ratio | 25.1% (improved) | n/a | `` |
| TTM net loss | ~¥10.2B | — | `` |
Read of the print:
, but the operating loss was **flat at ~−¥10B** because R&D hit a **record high** on pre-contract LEXI-P development . Operating leverage has not begun.. Management explicitly frames the company as in an **"investment-heavy phase, prioritising pipeline over near-term profitability"** and now guides **operating profitability only from FY2028 onward** .— the single most important number in this dossier. Equity ratio improved to 25.1% only because of the **¥30.6B raised in FY2026** (¥10.9B capital increase May 2025 + further financing). The improvement is financed, not earned.. The market did not punish the loss (it was guided); it punished the **backlog peak-out + the absence of a *new* growth story** post-earnings .No transcripts on the shelf; trend assembled from quarterly summaries ``.
Shift over time: the recurring phrase has migrated from commercial life-extension (LEXI-P) as the growth engine (FY2024–25) to government/defense pipeline as the engine (FY2026), precisely because the commercial contract kept slipping. They stopped saying "¥36B FY2026" and "LEXI-P revenue from FY2026"; they started saying "¥104B defense pipeline" and "FY2028 profitability." That migration is honest — but it is also the sound of a company changing its story when the first one didn't land on schedule.
Astroscale has no listed pure-play peer — the closest public comparators are diversified primes or different business models. Multiples are `` or n/a; none fabricated.
| Company | Ticker | Mkt cap (USD) | EV/Sales | P/E | Note |
|---|---|---|---|---|---|
| Astroscale Holdings | 186A.T | ~$1.05B (¥158B @ ¥150) `` | ~31x P/S `` | n/m (loss-making) | Pure-play OOS, pre-profit |
| Northrop Grumman (SpaceLogistics) | NOC | n/a | n/a | n/a | Prime; OOS is a tiny sub-segment (MEV-1/2 heritage) `` |
| Rocket Lab | RKLB | n/a | n/a | n/m | Launch + space systems; ADRAS-J launch provider `` |
| D-Orbit | private | n/a | — | — | LEO orbital-transfer leader `` |
| Starfish Space | private | ~$0.x B (Series B $100M+) `` | — | — | US gov's "most trusted RPO partner," $207M gov contracts `` |
| True Anomaly | private | ~$2.2B (Series D $650M, Apr 2026) `` | — | — | Defense-space; richer private mark than Astroscale's public cap |
| ClearSpace | private | n/a | — | — | ESA debris-removal contractor `` |
186A has only traded since June 2024, so the "5-year" window is a ~2-year IPO life. Moves >5% ``:
Pattern: this stock trades on (a) the space-sustainability theme and (b) milestone/guidance credibility — not on earnings (there are none). It is a high-beta thematic vehicle: 52-week range ¥575 → ¥3,015 (a >5x spread in one year). What the tape rewards is demonstrated mission progress + a credible escalating order story; what it punishes is slippage and a stale narrative. The June 2026 halving was a credibility de-rate, not a numbers miss.
n/a (no insider-transactions.csv). Strategic holders Mitsubishi Electric, Mitsubishi Corp, MUFG Bank, Development Bank of Japan participated in pre-IPO rounds ``.. The capital has gone into R&D and demonstration missions. ROIC is deeply negative by design (pre-profit). The honest read: management is **funding a moonshot with equity, and diluting holders ~16% in a year to do it** .Web-only; no audited filings on the shelf. Label all /; figures unaudited per the constraint.
. This is not improper — grant accounting is standard for development-stage gov contractors — **but it materially flatters the growth optics.** A reader who takes "+89% Project Income" as "+89% revenue" is misreading the business. Watch whether management leads with Project Income precisely *because* GAAP revenue is weaker (FY2026 GAAP revenue framing was actually *down* in some prior-year comparisons) .; net loss (−¥6.70B) is *smaller* than operating loss (−¥9.98B) due to **FX gains** — i.e. the bottom-line "beat" is partly non-operating currency luck, not operational improvement. Quality-of-earnings caution: do not extrapolate the FX tailwind.n/a and worth verifying in the audited statements.Regulatory findings (required sub-section).
"Astroscale Holdings" (FTC OR DOJ OR FDA OR consent decree OR settlement OR fine OR penalty) enforcement surfaced no material enforcement actions or settlements across the sources reviewed ``.n/a in English.This is a pre-profit, cash-runway story, not an EPS story — the right model is runway-to-inflection, and EPS stays negative across the explicit horizon. Building from FY2026 actuals + FY2027 guidance ``:
Anchors: FY2026 Project Income ¥11.5B, revenue ¥5.94B, operating loss −¥9.98B, net loss −¥6.70B, cash ¥10.0B, backlog ¥37.9B . Shares ~138.8M . Management guides operating profitability FY2028+ and steady-state SG&A "low ¥9B" from FY2028 ``.
| FY2027 (gd. Apr-27) | FY2028 (Apr-28) | FY2029 (Apr-29) | |
|---|---|---|---|
| Project Income | ¥14–17B `` | ¥20–25B `` | ¥28–35B `` |
| Operating loss | −¥9.0 to −9.9B `` | ~breakeven (mgmt target) / −¥2 to +¥1B | small positive `` |
| Net loss | −¥9.6 to −10.6B `` | −¥3 to −¥5B `` | −¥1B to breakeven `` |
| EPS (¥) | ~−¥69 to −76 `` (vs sell-side ~−¥53 on a higher prior share base) | ~−¥20 to −36 `` | ~−¥7 to 0 `` |
| Cash (pre-raise) | ~¥0–1B `` ⟹ raise required | post-raise dependent | — |
Forecast tracker: per the --watchlist rule, no forecast.ts create is logged in this unattended sweep. The natural binary to log later (in an attended pass): "Astroscale reaches full-year operating breakeven by FYE Apr-2028" — base-case p ≈ 0.30 `` (requires both the commercial signing and on-schedule mission execution, neither of which has a clean track record).
Bull case. Astroscale is the only listed pure-play in a category that has to exist: ~45,000 tracked objects and a tightening regulatory regime (FCC 5-year de-orbit rule, ESA zero-debris charter) make OOS structurally inevitable, and Astroscale owns the only demonstrated non-cooperative RPO heritage plus a three-bloc government-relationship moat and a ¥104B defense pipeline ``. If even a fraction of that pipeline converts to recurring orders — especially US/Japan defense refuelling and inspection, where budgets are growing and sovereignty concerns favour domestic-bloc vendors — the company crosses into recurring revenue and re-rates hard off a tiny ¥158B market cap. The CFO is a Goldman alum who can keep it funded; the founder has out-executed every commercial rival on actual flight heritage. The contrarian bull line: the market is pricing Astroscale as a failed commercial story while a defense story quietly ramps 3.5x in pipeline — re-rating risk is to the upside if FY2027 defense bookings surprise.
Bear case. Three things could permanently impair the equity: (1) the runway — under a year of cash against a structural ~¥10B/yr burn means certain dilution and a credibility-dependent ability to keep raising; if a raise fails or comes as a down-round, holders are crushed; (2) the commercial market may simply not arrive on schedule — LEXI-P (the flagship commercial life-extension contract) has slipped from FY2026 → FY2027 with the launch to FY2027, ELSA-M to "FY2028 or later," ADRAS-J2 to FY2027 — every commercial/flagship date has moved right, and a category that is perpetually "two years away" can stay that way for a decade; (3) competition is closing the heritage gap with deeper pockets (True Anomaly $2.2B, Starfish $207M in US gov contracts, Northrop's flown MEV heritage). Pre-mortem (18 months out, thesis broke): LEXI-P slipped again or cancelled, ELSA-M's launch on Isar's unproven Spectrum slipped or failed, backlog fell below ¥30B, the company raised equity ~20% dilutive at ~¥800, and the "defense pipeline" stayed a pipeline. At ~31x sales with flat losses guided, multiples are too high for a company still two-plus years from breakeven — the June 2026 halving may be a re-rate, not a bottom.
Contrarian view (what the market refuses to see): both tails are live and the consensus is too lazily bearish on the wrong axis. The market sold the commercial miss; the real option value — and the real risk — is defense. A single recurring US-Space-Force or Japan-MoD refuelling/inspection award would change the story overnight; equally, the market under-weights how binary the runway is. This is not a "fairly-valued GARP" name — it is a financed binary on a 2028 inflection.
Dismantling the bull case:
A debt-free, 59%-gross-margin device compounder mispriced as "space" — the real bet is whether the FY25–26 fitness-wearable share surge is a durable re-rating or a post-pandemic echo that decays back to mid-single-digit growth at a 24x multiple that already pays for the good case.
The only credible bet on FULL (both-stages) reuse besides SpaceX — a metallurgy/physics moat the others ducked — but it is a single-vehicle, zero-revenue, zero-flights company whose entire value is gated on one un-flown second stage surviving reentry; WATCHING, not investable, until Nova reaches orbit and the upper stage comes home intact.
A genuine launch-and-connectivity monopoly wrapped inside an unprofitable $2T+ aspiration stock — Starlink is the real business, but at ~110x sales the market is paying for Mars, orbital AI data centers, and a $60B Cursor bet that aren't earnings yet.